Association between citalopram serum levels and clinical improvement of patients with major depression / Haji Ostad en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 3 (Junio) . - pp. 281-286 Título : Association between citalopram serum levels and clinical improvement of patients with major depression Tipo de documento: texto impreso Autores: Haji Ostad, Autor ; Allahyari Elnaz, Autor ; André Tadic, Autor Fecha de publicación: 2022 Artículo en la página: pp. 281-286 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Antidepresivo, Citalopram, Concentración sérica, Monitorización de fármacos terapéuticos Resumen: Imaging studies have shown that serum concentrations of the selective serotonin reuptake inhibitor citalopram correlate with serotonin transporter (5-HTT) occupancy in vivo. In patients with major depressive disorders treated with citalopram, 80% 5-HTT occupancy was considered to be necessary for maximal therapeutic effects, which requires citalopram serum concentrations of at least 50 ng/mL. Link: ./index.php?lvl=notice_display&id=29374 [artículo] Association between citalopram serum levels and clinical improvement of patients with major depression [texto impreso] / Haji Ostad, Autor ; Allahyari Elnaz, Autor ; André Tadic, Autor . - 2022 . - pp. 281-286. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 3 (Junio) . - pp. 281-286 Palabras clave: Trastorno depresivo mayor, Antidepresivo, Citalopram, Concentración sérica, Monitorización de fármacos terapéuticos Resumen: Imaging studies have shown that serum concentrations of the selective serotonin reuptake inhibitor citalopram correlate with serotonin transporter (5-HTT) occupancy in vivo. In patients with major depressive disorders treated with citalopram, 80% 5-HTT occupancy was considered to be necessary for maximal therapeutic effects, which requires citalopram serum concentrations of at least 50 ng/mL. Link: ./index.php?lvl=notice_display&id=29374

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression -- The EMC trial / André Tadic en European Neuropsychopharmacology, Año 2016 - Vol. 26 - No. 4 (Abril)

Público ISBD [artículo]  inEuropean Neuropsychopharmacology > Año 2016 - Vol. 26 - No. 4 (Abril) . - pp. 705-716 Título : Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression -- The EMC trial Tipo de documento: texto impreso Autores: André Tadic, Autor ; Daniel Wachtlin, Autor ; Matthias Berger, Autor Fecha de publicación: 2021 Artículo en la página: pp. 705-716 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Antidepresivos, Farmacoterapia, RCT, Mejora temprana, Pautas Resumen: Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Link: ./index.php?lvl=notice_display&id=26570 [artículo] Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression -- The EMC trial [texto impreso] / André Tadic, Autor ; Daniel Wachtlin, Autor ; Matthias Berger, Autor . - 2021 . - pp. 705-716. Idioma : Inglés (eng) Idioma original : Inglés (eng) in European Neuropsychopharmacology > Año 2016 - Vol. 26 - No. 4 (Abril) . - pp. 705-716 Palabras clave: Trastorno depresivo mayor, Antidepresivos, Farmacoterapia, RCT, Mejora temprana, Pautas Resumen: Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Link: ./index.php?lvl=notice_display&id=26570

---

1 (1 - 2 / 2)